Third Line Trials
| ClinicalTrials.gov Identifier: |
NCT05118789 |
This study is currently recruiting participants.
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors.
Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors.
Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-520 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors.
Alberta
Cross Cancer Institute, Edmonton
Principal Investigator: Quincy Chu, MD
Ontario
Princess Margaret Cancer Research, Toronto
Principal Investigator: Geoffrey Liu, MD
| ClinicalTrials.gov Identifier: |
NCT04919811 |
This study is currently recruiting participants.
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Ontario
Princess Margaret Cancer Centre, Toronto
Quebec
McGill University Health Centre Research Institute, Montréal
| ClinicalTrials.gov Identifier: |
NCT05067283 |
This study is currently recruiting participants.
This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.
Ontario
Hamilton Health Sciences, Juravinski Cancer Centre
Princess Margaret Cancer Centre, Toronto
| ClinicalTrials.gov Identifier: |
NCT05384626 |
This study is currently recruiting participants.
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.
Phase 1 will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors.
Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.
Alberta
Cross Cancer Institute, Edmonton
Principal Investigator: Quincy Siu Chung Chu, MD
Ontario
Princess Margaret Cancer Centre, Toronto
Principal Investigator: Geoffrey Liu, M.D.
| ClinicalTrials.gov Identifier: |
NCT03739710 |
This study is currently recruiting participants
This study will compare the clinical activity of novel immune-oncology agents (in combination or as single agents) to standard of care in participants with relapsed/refractory advanced NSCLC. The study will initially evaluate two treatment regimens/arms. Additional regimens/arms may be added via future protocol amendment(s). Participants will be stratified by histology (squamous vs. non-squamous) and line of anti-programmed cell death ligand 1 (PD[L]1) therapy (first vs. second line). Initially, the study will evaluate the GSK3359609 inducible T-cell co-stimulator (ICOS) agonist in combination with SoC docetaxel compared to docetaxel alone (sub-study 1). SoC arm will be the common comparison arm across all sub-studies. At study start, subjects will be randomized to the study at a ratio of 1:2 to Arm 1 (docetaxel) and Arm 2 (ICOS agonist + docetaxel). The study will consist of three periods: Screening, Treatment, and Follow-Up. There will be approximately 105 participants enrolled in the study initially. Treatment will continue for approximately 2 years and participants will be followed for survival during the follow-up period.
| Alberta |
| GSK Investigational Site |
|
| Edmonton, Alberta, Canada, T6G 1Z2 |
Principal Investigator: Quincy Chu
|
| Ontario |
| GSK Investigational Site |
|
| Brampton, Ontario, Canada, L6R 3J7 |
Principal Investigator: Parneet Cheema
|
| GSK Investigational Site |
|
| Ottawa, Ontario, Canada, K1H 8L6 |
Principal Investigator: Paul Wheatley-Price
|
| GSK Investigational Site |
|
Toronto, Ontario, Canada, M5G 2M9
|
| ClinicalTrials.gov Identifier: |
NCT04154956 |
This study is currently recruiting participants
The primary objective is to determine whether SAR408701 improves the progression free survival (PFS) when compared to docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 ≥2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor (ICI).
Quebec
Greenfield Park, Montreal
| ClinicalTrials.gov Identifier: |
NCT04727151 |
This study is currently active and recruiting participants
TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor.
This is an open-label, multicenter Phase 1/2 study that aims to establish safety, Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 in subjects with relapsed or refractory solid tumors.
Ontario
Princes Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT03093116 |
This study is currently active and recruiting participants
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.
Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Alberta
Edmonton
British Colombia
Vancouver
Ontario
Brampton
Ottawa
Toronto
| ClinicalTrials.gov Identifier: |
NCT02912949 |
This study is currently active and recruiting participants
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Ontario
Toronto
| ClinicalTrials.gov Identifier: |
NCT04449874 |
This study is currently active and recruiting participants
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Ontario
Ottawa
Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT04335292 |
This study is currently recruiting participants.
This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy.
The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertinib follows its use in approved settings. The investigators examine its tolerability and efficacy in this setting to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).
British Colombia
Vancouver
Ontario
Brampton
Hamilton
Kitchener
London
Oshawa
Ottawa
Toronto
| ClinicalTrials.gov Identifier: |
NCT03645928 |
This study is currently recruiting participants.
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.
Ontario
Princess Margaret Cancer Centre, Toronto
| ClinicalTrials.gov Identifier: |
NCT03175224 |
This study is currently active and recruiting participants
The primary Phase 1 purpose of this study was to assess overall safety, tolerability and recommended Phase 2 dose (RP2D) of APL-101.
The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers associated with c-Met amplifications; individuals with cancers associated with c-Met fusion
Alberta
Cross Cancer Institute, Edmonton
Manitoba
CancerCare Manitoba, Winnipeg
Ontario
Princess Margaret Hospital, Toronto
Quebec
McGill University Health Center, Montreal
| ClinicalTrials.gov Identifier: |
NCT04931654 |
This study is currently recruiting participants.
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
Ontario
Toronto
| ClinicalTrials.gov Identifier: |
NCT04931654 |
This study is currently active and recruiting participants
This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC. Drug name mentioned as GSK4428859A and EOS884448 are interchangeable for the same compound and will be referred to as GSK4428859A/EOS884448.
Alberta
Edmonton, Alberta, Canada, T6G 1Z2
Principal Investigator: Quincy Chu
Ontario
Brampton, Ontario, Canada, L6R 3J7
Principal Investigator: Parneet Cheema
Toronto, Ontario, Canada, M5G 2M9
Principal Investigator: Adrian Sacher
| ClinicalTrials.gov Identifier: |
NCT04862780 |
This study is currently recruiting participants.
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.
Ontario
Princess Margaret Cancer Centre, Toronto
| ClinicalTrials.gov Identifier: |
NCT04084717 |
This study is currently active and recruiting participants
This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer.
Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.
Ontario
Princess Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT0538869 |
This study is active, but not recruiting participants.
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
Ontario
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, K1H 8L6
Princess Margaret Hospital, Toronto, Ontario, Canada, M5G 1Z5
| ClinicalTrials.gov Identifier: |
NCT02609776 |
This study is active, but not recruiting participants
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
British Columbia
Vancouver
Ontario
University Health Network, Toronto
| ClinicalTrials.gov Identifier: |
NCT02393625 |
This study is currently active but not recruiting participants
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients.
Ontario
Toronto, Ontario, M5G 2M9
| ClinicalTrials.gov Identifier: |
NCT02503722 |
This study is currently active but not recruiting participants
This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
| British Columbia |
| BCCA-Vancouver Cancer Centre |
|
| Vancouver, British Columbia, Canada, V5Z 4E6 |
| Contact: Site Public Contact, 888-939-3333 |
Principal Investigator: Cheryl Ho
|
| Ontario |
| University Health Network-Princess Margaret Hospital |
|
| Toronto, Ontario, Canada, M5G 2M9 |
| Contact: Site Public Contact, 416-946-4501 [email protected] |
| Principal Investigator: Penelope A. Bradbury |
| ClinicalTrials.gov Identifier: |
NCT02414139 |
This study is currently active but not recruiting participants
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC).
Ontario
Novartis Investigative Site
Ottawa, Ontario, K1H 8L6
| ClinicalTrials.gov Identifier: |
NCT03539536 |
This study is currently active but not recruiting participants
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Alberta
Cross Cancer Institute, Edmonton
Ontario
Ottawa Hospital, Ottawa
Princess Margaret Hospital, Toronto
Quebec
CISSS de la Monteregie, Greenfield Park
| ClinicalTrials.gov Identifier: |
NCT03976375 |
This study is currently active but not recruiting participants
This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb).
Manitoba
CancerCare Manitoba (Site 1504)
Ontario
Kingston Health Sciences Centre (Site 1503)
London Regional Cancer Program - London HSC (Site 1505)
Princess Margaret Cancer Centre - Toronto (Site 1502)
Quebec
CIUSSS Ouest de l'Ile - St Mary's Hospital - Montreal (Site 1501)
CHU de Quebec - Universite Laval - Hotel Dieu de Quebec (Site 1514)
| ClinicalTrials.gov Identifier: |
NCT03596866 |
This study is active but not recruiting participants
The purpose of this study is to compare the efficacy of brigatinib versus alectinib in participants with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have progressed on crizotinib as evidenced by progression free survival as assessed by a blinded independent review committee (BIRC) utilizing response evaluation criteria in solid tumors (RECIST) v1.1.
Nova Scotia
| Queen Elizabeth II Health Sciences Centre |
|
Halifax, Nova Scotia, Canada, B3H 1V7
|
|
| Ontario |
| Toronto University Health Network |
|
| Toronto, Ontario, Canada, M5G 2M9 |
| ClinicalTrials.gov Identifier: |
NCT03535740 |
This study is currently active but not recruiting participants
The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.
| Alberta |
| Cross Cancer Institute |
|
| Edmonton, Alberta, Canada, T6G 1Z2 |
| |
| Tom Baker Cancer Center |
|
Calgary, Alberta, Canada, T2N 2T9
|
| Ontario |
| Toronto University Health Network |
|
Toronto, Ontario, Canada, M5G 2M9
|
| Quebec |
| McGill University Health Centre |
|
| Montreal, Quebec, Canada, H4A 3J1 |
| ClinicalTrials.gov Identifier: |
NCT03334617 |
This study is currently active but not recruiting participants
This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Alberta
Research Site Edmonton
Ontario
Research Site Brampton
Research Site Ottawa
Research Site Toronto
Quebec
Research Site Montreal
| ClinicalTrials.gov Identifier: |
NCT03906071 |
This study is active but not recruiting participants
his study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Ontario
Princess Margaret Hospital Toronto
| ClinicalTrials.gov Identifier: |
NCT03596866 |
This study is active but not recruiting participants
The purpose of this study is to compare the efficacy of brigatinib versus alectinib in participants with ALK+ locally advanced or metastatic NSCLC who have progressed on crizotinib as evidenced by progression-free survival (PFS) as assessed by response evaluation criteria in solid tumors (RECIST) v1.1.
Nova Scotia
Queen Elizabeth II Health Sciences Centre, Halifax
Ontario
University Health Network, Toronto
| ClinicalTrials.gov Identifier: |
NCT03333343 |
This study is currently active but not recruiting participants.
The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced EGFR-mutant NSCLC.
Ontario
Toronto
| ClinicalTrials.gov Identifier: |
NCT03318939 |
This study is active but not recruiting participants
This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients.
Alberta
Cross Cancer Institute, Edmonton
Ontario
London Regional Cancer Program, London
Princess Margaret Hospital, Toronto
British Columbia
BC Cancer, Vancouver